Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Kuros Biosciences's enterprise value is CHF763.3 Mil.
Kuros Biosciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was CHF8.8 Mil. Therefore, Kuros Biosciences's EV-to-EBITDA for today is 87.19.
The historical rank and industry rank for Kuros Biosciences's EV-to-EBITDA or its related term are showing as below:
XSWX:KURN'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -1932.33 Med: -3.19 Max: 131.31
Current: 87.19
During the past 13 years, the highest EV-to-EBITDA of Kuros Biosciences was 131.31. The lowest was -1932.33. And the median was -3.19.
XSWX:KURN's EV-to-EBITDA is ranked worse than 95.29% of 510
companies
in the Medical Devices & Instruments industry
Industry Median: 14.115
vs XSWX:KURN: 87.19
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Kuros Biosciences (XSWX:KURN) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Kuros Biosciences's PE Ratio (TTM) for today is calculated as:
Kuros Biosciences's share price for today is CHF19.80.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Kuros Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was CHF0.070.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Kuros Biosciences's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:KURN vs ABT, SYK, MDT: EV-to-EBITDA Comparison
For the Medical Devices subindustry, Kuros Biosciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kuros Biosciences EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Kuros Biosciences's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Kuros Biosciences's EV-to-EBITDA falls into.
Kuros Biosciences's current Enterprise Value is CHF763.3 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Kuros Biosciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was CHF8.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kuros Biosciences (XSWX:KURN) has a EV-to-EBITDA of 87.19 as of Jul. 27, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Kuros Biosciences. According to the industry distribution chart, Kuros Biosciences ranks #486 out of 510 companies in the Medical Devices & Instruments industry, placing it in the top 95.3%.
Is Kuros Biosciences' EV-to-EBITDA too high?
Kuros Biosciences' current EV-to-EBITDA is 87.19. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.12. Kuros Biosciences' value of 87.19 is 517.7% above this industry median. Based on the distribution chart, Kuros Biosciences ranks #486 out of 510 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Kuros Biosciences has a GF Score™ of 63/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kuros Biosciences' EV-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Kuros Biosciences ranks #486 out of 510 companies for EV-to-EBITDA. This places Kuros Biosciences in the lower half of its industry. The industry median EV-to-EBITDA is 14.12. Kuros Biosciences' value of 87.19 is 517.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.12, based on 510 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kuros Biosciences's current EV-to-EBITDA of 87.19 is 517.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Kuros Biosciences. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kuros Biosciences's current EV-to-EBITDA is 87.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kuros Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Kuros Biosciences (XSWX:KURN) is currently considered Significantly Undervalued. The stock's GF Value™ is CHF37.22, compared to a current price of CHF19.80 — trading 46.8% below its estimated fair value. The current EV-to-EBITDA is 87.19 and 517.7% above the Medical Devices & Instruments industry median of 14.12. Kuros Biosciences' overall GF Score™ is 63/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Kuros Biosciences (XSWX:KURN), the current EV-to-EBITDA is 87.19 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kuros Biosciences (XSWX:KURN) Overvalued in 2026?
Based on GuruFocus' analysis, Kuros Biosciences stock appears to be undervalued.
The current stock price of CHF19.80 is trading 46.8% below its estimated GF Value™ of CHF37.22.
GuruFocus considers Kuros Biosciences to be Significantly Undervalued.
Key valuation signals for XSWX:KURN:
EV-to-EBITDA: 87.19
GF Value™: CHF37.22 vs. price of CHF19.80 (46.8% below fair value)
Industry Position: 517.7% above the Medical Devices & Instruments median (#486 of 510)
No single metric tells the full story. See the XSWX:KURN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kuros Biosciences Ltd is a Swiss-based biotech company, focused on developing and commercializing biologic bone graft technologies for musculoskeletal applications, particularly in spine, trauma, extremities, and oncology. It has two reportable segments: i) Medical Devices: This segment includes products such as MagnetOs and Attrax, which are biphasic calcium phosphate (BCP) bone grafts that mimic the porous, trabecular structure of cancellous bone. ii) Legacy Portfolio: This segment includes all non-core products (including Checkmate licensing) that are outside the Group's primary therapeutic focus. The majority of the company's revenue is derived from the Medical Devices segment. Geographically, it generates the maximum revenue from the United States of America.
63GF Score
Get the complete analysis for XSWX:KURN
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:KURN has been successfully added to your 
